DV
Dividend Vision

AAPG — Ascentage Pharma Group International

Ascentage Pharma Group International (AAPG)

Total return is 9.3% over the past 1.6 years, 20.6 points behind SPY at 29.9%. Its deepest 1-year drawdown was 65.2%.

Ascentage Pharma Group International is a clinical-stage biotechnology company developing therapies for cancers, chronic hepatitis B, and age-related diseases, with multiple drug candidates in development including HQP1351 for BCR-ABL mutants and several oral inhibitors targeting various oncology indications. The company does not currently distribute dividends. Ascentage appeals to investors seeking exposure to early-stage biotech development with a focus on oncology and viral disease treatments in the Chinese market.

AAPG key facts

Asset type
Stock
Asset class
Equity
Inception date
01/24/2025
Last close
$19.00
Market cap
$1,749,139,456
Average volume
186.0
Beta
0.659
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.05